Literature DB >> 25079302

Nemonoxacin: first global approval.

Raewyn M Poole1.   

Abstract

Nemonoxacin (Taigexyn(®)), a non-fluorinated quinolone antibacterial agent, is under development with TaiGen Biotechnology for the oral and intravenous treatment of community-acquired pneumonia (CAP) and the oral treatment of diabetic foot ulcer infections and skin and soft tissue infections. Oral nemonoxacin has been approved in Taiwan for the treatment of CAP in adults. This article summarizes the milestones in the development of nemonoxacin leading to this first approval for the treatment of CAP.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25079302     DOI： 10.1007/s40265-014-0270-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  22 in total

1.  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  Kobkul Chotikanatis; Stephan A Kohlhoff; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

2.  Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.

Authors:  Chih-Cheng Lai; Wei-Lun Liu; Wen-Chien Ko; Yen-Hsu Chen; Hon-Ren Tan; Yu-Tsung Huang; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.

Authors:  Chun-Hsing Liao; Wen-Chien Ko; Jang-Jih Lu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

4.  Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.

Authors:  Yi-Chun Lin; Yu-Tsung Huang; Pei-Jane Tsai; Tai-Fen Lee; Nan-Yao Lee; Chun-Hsing Liao; Shyr-Yi Lin; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

5.  Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.

Authors:  Beining Guo; Xiaojie Wu; Yingyuan Zhang; Yaoguo Shi; Jicheng Yu; Guoying Cao; Jing Zhang
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

6.  In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.

Authors:  Yen-Hsu Chen; Chia-Ying Liu; Jang-Jih Lu; Chi-Hsin R King; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2009-10-14       Impact factor: 5.790

7.  Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.

Authors:  David T Chung; Cheng-Yuan Tsai; Shu-Jen Chen; Li-Wen Chang; Chi-Hsin R King; Ching-Hung Hsu; Kit-Mui Chiu; Hao-Chen Tan; Yu-Ting Chang; Ming-Chu Hsu
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

8.  Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.

Authors:  Chih-Cheng Lai; Che-Kim Tan; Sheng Hsiang Lin; Chun-Hsing Liao; Chien-Hong Chou; Hsiao-Leng Hsu; Yu-Tsung Huang; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2009-04-27       Impact factor: 5.790

Review 9.  The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review.

Authors:  Leon Peto; Behzad Nadjm; Peter Horby; Ta Thi Dieu Ngan; Rogier van Doorn; Nguyen Van Kinh; Heiman F L Wertheim
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-04-29       Impact factor: 2.184

Review 10.  Etiologies and resistance profiles of bacterial community-acquired pneumonia in Cambodian and neighboring countries' health care settings: a systematic review (1995 to 2012).

Authors:  Sophie Goyet; Erika Vlieghe; Varun Kumar; Steven Newell; Catrin E Moore; Rachel Bousfield; Heng C Leang; Sokheng Chuop; Phe Thong; Blandine Rammaert; Sopheak Hem; Johan van Griensven; Agus Rachmat; Thomas Fassier; Kruy Lim; Arnaud Tarantola
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240
View more
  9 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 2.  Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.

Authors:  Yu-Xuan Ma; Chen-Yu Wang; Yuan-Yuan Li; Jing Li; Qian-Qian Wan; Ji-Hua Chen; Franklin R Tay; Li-Na Niu
Journal:  Adv Sci (Weinh)       Date:  2019-12-05       Impact factor: 16.806

Review 3.  Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.

Authors:  B Amalakuhan; K L Echevarria; M I Restrepo
Journal:  Expert Opin Pharmacother       Date:  2017-06-21       Impact factor: 3.889

Review 4.  Transferable Mechanisms of Quinolone Resistance from 1998 Onward.

Authors:  Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

5.  Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Dynamic Pharmacokinetic/Pharmacodynamic Model.

Authors:  Junchen Huang; Siwei Guo; Xin Li; Fang Yuan; You Li; Bing Xu; Junyuan Gu; Yong Qiao
Journal:  Antimicrob Agents Chemother       Date:  2021-12-13       Impact factor: 5.938

Review 6.  Post-Translational Modifications in NETosis and NETs-Mediated Diseases.

Authors:  Hussein J Hamam; Nades Palaniyar
Journal:  Biomolecules       Date:  2019-08-14

Review 7.  Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.

Authors:  Ioana-Andreea Lungu; Octavia-Laura Moldovan; Victoria Biriș; Aura Rusu
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

8.  In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.

Authors:  Siddhartha Roychoudhury; Kelly Makin; Tracy Twinem; Robert Leunk; Ming Chu Hsu
Journal:  Microb Drug Resist       Date:  2016-06-07       Impact factor: 3.431

Review 9.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.